Allogene sets sights on iPS cell-based allogeneic therapies via Notch partnership

Allogene has staked its claim in iPS cell-based allogeneic therapies by partnering with Notch to develop T cell and NK cell therapies to treat non-Hodgkin lymphoma, leukemia and multiple myeloma.

Moving beyond healthy donor cells to use iPS cells for allogeneic therapies is “what we see as the evolution of the field and the future of cell therapy,” Allogene Therapeutics Inc. (NASDAQ:ALLO) President and CEO David Chang told BioCentury. “This is a space we have to have a play in.”...